Skip to main content
Equibles
PBYI logo

PBYI · Puma Biotechnology, Inc. · Earnings Call Transcripts & Audio

Track PBYI — free

Use PBYI with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research PBYI.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$9.59 -0.01 (-0.10%) At close · Sep 21
Russell 2000 member Rebalance outlook locked
Market Cap
$495.55M
Shares
51.62M

Puma Biotechnology, Inc. Earnings Call Transcripts

Quarterly earnings calls for Puma Biotechnology, Inc. (PBYI), with available speaker-labelled transcripts, captured audio replays, call highlights, 8-K earnings releases and periodic filings. Investor days and conferences appear here too.

Pull transcripts and briefs through the earnings call transcript API or MCP →

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
▲23.5% $57.10M −$360,000 '22 Q3 22-11-03 ▲18.6% $65.67M −$5.61M '22 Q4 23-03-02 ▲15.4% $52.77M $1.40M '23 Q1 23-05-04 ▼8.3% $54.57M $2.13M '23 Q2 23-08-03 ▼1.7% $56.12M $5.80M '23 Q3 23-11-02 ▲9.9% $72.18M $12.27M '23 Q4 24-02-29 ▼17.1% $43.77M −$4.82M '24 Q1 24-05-02 ▼13.7% $47.08M −$4.53M '24 Q2 24-08-01 ▲43.5% $80.54M $20.32M '24 Q3 24-11-07 ▼18.2% $59.08M $19.30M '24 Q4 25-02-27 ▲5.1% $46.01M $2.97M '25 Q1 25-05-08 ▲11.4% $52.44M $5.86M '25 Q2 25-08-07 ▼32.4% $54.48M $8.84M '25 Q3 25-11-06 ▲27.7% $75.45M $13.44M '25 Q4 26-02-26 ▼2.6% $44.81M −$3.75M '26 Q1 26-05-07 LATEST ▲7.8% $56.50M $8.19M '26 Q2 26-08-06
Conference
Investor event
2026-09-14
Puma Biotechnology, Inc. (PBYI) September 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q2
2026-08-06
Puma Biotechnology, Inc. (PBYI) Q2 2026 Earnings Call Transcript
Positive tone Breast cancer unmet need and marketing Financial discipline and positive net income Trial dosing and protocol amendments
Revenue
$56.50M
▲ 7.8% YoY
Diluted EPS
$0.16
▲ 33.3% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q1
2026-05-07
Puma Biotechnology, Inc. (PBYI) Q1 2026 Earnings Call Transcript
Positive tone Alisca Lung-1 Phase II trial Unmet medical need / company mission Dose escalation
Revenue
$44.81M
▼ 2.6% YoY
Diluted EPS
$-0.07
▼ 216.7% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-02-26
Puma Biotechnology, Inc. (PBYI) Q4 2025 Earnings Call Transcript
Positive tone NERLYNX Commercial Performance ALISCA-Lung1 Trial ALISCA-Breast1 Trial
Revenue
$75.45M*
▲ 27.7% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-06
Puma Biotechnology, Inc. (PBYI) Q3 2025 Earnings Call Transcript
Positive tone NERLYNX commercial performance Alisertib ALISCA-Breast1 trial Regulatory and development path for alisertib
Revenue
$54.48M
▼ 32.4% YoY
Diluted EPS
$0.17
▼ 58.5% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-07
Puma Biotechnology, Inc. (PBYI) Q2 2025 Earnings Call Transcript
Positive tone ALISCA-Breast Phase II trial NERLYNX commercial performance ALISCA-Lung1 Phase II trial
Revenue
$52.44M
▲ 11.4% YoY
Diluted EPS
$0.12
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-08
Puma Biotechnology, Inc. (PBYI) Q1 2025 Earnings Call Transcript
Positive tone NERLYNX commercial performance Alisertib clinical development Neratinib combination data with Enhertu
Revenue
$46.01M
▲ 5.1% YoY
Diluted EPS
$0.06
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-02-27
Puma Biotechnology, Inc. (PBYI) Q4 2024 Earnings Call
Revenue
$59.08M*
▼ 18.2% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-07
Puma Biotechnology, Inc. (PBYI) Q3 2024 Earnings Call Transcript
Positive tone Alisertib safety / tolerability profile Royalty revenue from China/Pierre Fabre NERLYNX commercial performance
Revenue
$80.54M
▲ 43.5% YoY
Diluted EPS
$0.41
▲ 241.7% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-01
Puma Biotechnology, Inc. (PBYI) Q2 2024 Earnings Call Transcript
Positive tone Alisertib clinical development NERLYNX commercial performance Royalty revenue and China dynamics
Revenue
$47.08M
▼ 13.7% YoY
Diluted EPS
$-0.09
▼ 280% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-02
Puma Biotechnology, Inc. (PBYI) Q1 2024 Earnings Call Transcript
Balanced tone Alisertib clinical pipeline NERLYNX product revenue decline Sales force and HCP engagement
Revenue
$43.77M
▼ 17.1% YoY
Diluted EPS
$-0.10
▼ 433.3% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-02-29
Puma Biotechnology, Inc. (PBYI) Q4 2023 Earnings Call Transcript
Positive tone Alisertib Pipeline Development NERLYNX Commercial Performance Business Development and In-Licensing
Revenue
$72.18M*
▲ 9.9% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-02
Puma Biotechnology, Inc. (PBYI) Q3 2023 Earnings Call Transcript
Revenue
$56.12M
▼ 1.7% YoY
Diluted EPS
$0.12
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-03
Puma Biotechnology, Inc. (PBYI) Q2 2023 Earnings Call Transcript
Revenue
$54.57M
▼ 8.3% YoY
Diluted EPS
$0.05
▼ 76.2% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-04
Puma Biotechnology, Inc. (PBYI) Q1 2023 Earnings Call Transcript
Revenue
$52.77M
▲ 15.4% YoY
Diluted EPS
$0.03
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-03-02
Puma Biotechnology, Inc. (PBYI) Q4 2022 Earnings Call Transcript
Revenue
$65.67M*
▲ 18.6% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-03
Puma Biotechnology, Inc. (PBYI) Q3 2022 Earnings Call Transcript
Revenue
$57.10M
▲ 23.5% YoY
Diluted EPS
$-0.01
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-04
Puma Biotechnology, Inc. (PBYI) Q2 2022 Earnings Call Transcript
Revenue
$59.52M
▲ 11.5% YoY
Diluted EPS
$0.21
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-05
Puma Biotechnology, Inc. (PBYI) Q1 2022 Earnings Call Transcript
Revenue
$45.74M
▼ 53.4% YoY
Diluted EPS
$-0.08
▼ 120% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-03-03
Puma Biotechnology, Inc. (PBYI) Q4 2021 Earnings Call Transcript
Revenue
$55.36M*
▲ 5.3% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-04
Puma Biotechnology, Inc. (PBYI) Q3 2021 Earnings Call Transcript
Revenue
$46.24M
▼ 8.9% YoY
Diluted EPS
$-1.09
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-05
Puma Biotechnology, Inc. (PBYI) Q2 2021 Earnings Call Transcript
Revenue
$53.38M
▼ 24.4% YoY
Diluted EPS
$-0.13
▼ 262.5% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-05-06
Puma Biotechnology, Inc. (PBYI) Q1 2021 Earnings Call Transcript
Revenue
$98.17M
▲ 91.7% YoY
Diluted EPS
$0.40
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-02-25
Puma Biotechnology, Inc. (PBYI) Q4 2020 Earnings Call Transcript
Revenue
$52.56M
▼ 16.5% YoY
Diluted EPS
$-0.38
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-11-05
Puma Biotechnology, Inc. (PBYI) Q3 2020 Earnings Call Transcript
Revenue
$50.75M
▼ 9.9% YoY
Diluted EPS
$-0.79
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-08-06
Puma Biotechnology, Inc. (PBYI) Q2 2020 Earnings Call Transcript
Revenue
$70.58M
▲ 30.9% YoY
Diluted EPS
$0.08
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q1
2020-05-07
Puma Biotechnology, Inc. (PBYI) Q1 2020 Earnings Call Transcript
Revenue
$51.22M
▼ 48.3% YoY
Diluted EPS
$-0.43
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY19 · Q4
2020-02-20
Puma Biotechnology, Inc. (PBYI) Q4 2019 Earnings Call
Revenue
$62.92M
▼ 11.5% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Showing 1–28 of 28 earnings calls
Key facts CIK 1401667 CUSIP 74587V107 13F (30d) 2 filings 2 filers Visit website Investor relations